Spain Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Related Markets
Spain recombinant protein therapeutics cdmo market highlights
- The Spain recombinant protein therapeutics cdmo market generated a revenue of USD 617.2 million in 2023 and is expected to reach USD 1,566.9 million by 2030.
- The Spain market is expected to grow at a CAGR of 14.2% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 617.2 million |
| Market revenue in 2030 | USD 1,566.9 million |
| Growth rate | 14.2% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Spain accounted for 3.0% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 2,892.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.42% in 2023. Horizon Databook has segmented the Spain recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
For instance, according to Invest in Spain, Spain is one of Europe's principal markets, with 1,000+ companies wherein 500 of them are manufacturers. Moreover, several major companies choose the country as the destination for investment, not only to distribute products but to establish R&D, production, & service centers.
For instance, in December 2023, the Spanish CDMO Lean bio was set to invest an additional USD 22 million into a facility being constructed near Barcelona. The upcoming site is designed to accommodate three production lines capable of manufacturing recombinant proteins & antibodies, along with plasmid DNA and messenger RNA.
In addition, the high demand for medicines in the country due to the high burden of chronic diseases is promoting the demand for recombinant protein therapeutics CDMO in the country. A rise in the number of manufacturing facilities in the country is anticipated to fuel market growth. For instance, in March 2023, 3P Biopharmaceuticals (3P), a CDMO specializing in process development and cGMP manufacturing of biological products, began expanding its capabilities in protein production. This includes the installation of a new 500-liter stainless steel fermenter with fermentation technology, complementing its existing capacity for protein production from bacteria & yeast.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Enzene Biosciences | View profile | 251-500 | Pune, Maharashtra, India, Asia | http://www.enzene.com/ |
| Biovian | View profile | 101-250 | Turku, Western Finland, Finland, Europe | http://www.biovian.com |
| HALIX | View profile | 11-50 | Leiden, Zuid-Holland, The Netherlands, Europe | https://www.halix.nl |
| Richter-Helm | View profile | 251-500 | Hamburg, Hamburg, Germany, Europe | http://www.richter-helm.eu |
| Batavia Biosciences | View profile | 101-250 | Leiden, Zuid-Holland, The Netherlands, Europe | http://www.bataviabiosciences.com/ |
| Curia | View profile | 1001-5000 | Albany, New York, United States, North America | https://curiaglobal.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Spain recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Spain Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
